Drug Trial Radar · NCT03336333
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
590
Actual
Start
Oct 31, 2017
Primary completion
May 7, 2021
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
ZanubrutinibDrug
Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
BendamustineDrug
Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.
RituximabDrug
Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6
VenetoclaxDrug
400 mg tablets administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)Time frame: Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021)
Locations
158 sites in 15 countries. Site status is shown where the registry gives one.
Augusta University
Augusta, Georgia
Northwestern University
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Research Medical Center
Kansas City, Missouri
Washington University
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Summit Medical Group
Florham Park, New Jersey
Icahn School of Medicine At Mount Sinai
New York, New York
Columbia University Medical Center
New York, New York
University of Rochester
Rochester, New York
Duke University
Durham, North Carolina
Oregon Health and Science University
Portland, Oregon
Prairie Lakes Healthcare System
Watertown, South Dakota
Tennessee Oncology, Pllc Nashville
Nashville, Tennessee
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas
University of Virginia
Charlottesville, Virginia
Va Puget Sound Health Care System
Seattle, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
Concord Repatriation General Hospital
Concord, New South Wales, Australia
The Tweed Valley Hospital
Cudgen, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Royal Brisbane and Womens Hospital
Herston, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Health
Clayton, Victoria, Australia
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia
Peninsula Private Hospital
Frankston, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Medizinische Universitatsklinik Innsbruck
Innsbruck, Austria
Krankenhaus Der Barmherzigen Schwestern Linz
Linz, Austria
Allgemeines Krankenhaus Der Stadt Linz
Linz, Austria
Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
Salzburg, Austria
Klinikum Wels Grieskirchen
Wels, Austria
Universitair Ziekenhuis Brussel
Brussels, Belgium
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.